Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 26

Get the latest international news and world events from around the world.

Log in for authorized contributors

One of the world’s oldest blood pressure drugs may also halt aggressive brain tumor growth

A Penn-led team has revealed how hydralazine, one of the world’s oldest blood pressure drugs and a mainstay treatment for preeclampsia, works at the molecular level. In doing so, they made a surprising discovery—it can also halt the growth of aggressive brain tumors.

Over the last 70 years, hydralazine has been an indispensable tool in medicine—a front-line defense against life-threatening , especially during pregnancy. But despite its essential role, a fundamental mystery has persisted: No one knows its “mechanism of action”—essentially how it works at a molecular level, which allows for improved efficacy, safety, and what it can treat.

“Hydralazine is one of the earliest vasodilators ever developed, and it’s still a first-line treatment for preeclampsia—a hypertensive disorder that accounts for 5%–15% of worldwide,” says Kyosuke Shishikura, a physician-scientist at the University of Pennsylvania. “It came from a ‘pre-target’ era of , when researchers relied on what they saw in patients first and only later tried to explain the biology behind it.”

From body fat to bone, experiment offers hope for ‘gentle’ repair of fractures

Japanese researchers are testing a surprising, minimally invasive way to repair spine fractures.

A team at Osaka Metropolitan University found that stem cells from can repair breaks similar to those common in people with the bone-weakening disease osteoporosis.

“This simple and effective method can treat even difficult fractures and may accelerate healing,” said study co-leader Dr. Shinji Takahashi, an orthopedic surgeon and clinical lecturer at the university.

From Data to Physics: An Agentic Large Language Model Solves a Competitive Adsorption Puzzle

We show that an agentic large language model (LLM) (OpenAI o3 with deep research) can autonomously reason, write code, and iteratively refine hypotheses to derive a physically interpretable equation for competitive adsorption on metal-organic layers (MOLs)—an open problem our lab had struggled with for months. In a single 29-min session, o3 formulated the governing equations, generated fitting scripts, diagnosed shortcomings, and produced a compact three-parameter model that quantitatively matches experiments across a dozen carboxylic acids.

Tim Cook

Timothy Donald Cook (born November 1, 1960) [ 1 ] is an American business executive who is the current chief executive officer of Apple. Cook had previously been the company’s chief operating officer under its co-founder Steve Jobs. [ 2 ] Cook joined Apple in March 1998 as a senior vice president for worldwide operations, and then as vice president for worldwide sales and operations. [ 3 ] He was appointed chief executive of Apple on August 24, 2011, after Jobs resigned.

Bridging Retinal and Cerebral Neurodegeneration: A Focus on Crosslinks between Alzheimer–Perusini’s Disease and Retinal Dystrophies

In the early stages of Alzheimer–Perusini’s disease (AD), individuals often experience vision-related issues such as color vision impairment, reduced contrast sensitivity, and visual acuity problems. As the disease progresses, there is a connection with glaucoma and age-related macular degeneration (AMD) leading to retinal cell death. The retina’s involvement suggests a link with the hippocampus, where most AD forms start. A thinning of the retinal nerve fiber layer (RNFL) due to the loss of retinal ganglion cells (RGCs) is seen as a potential AD diagnostic marker using electroretinography (ERG) and optical coherence tomography (OCT). Amyloid beta fragments (Aβ), found in the eye’s vitreous and aqueous humor, are also present in the cerebrospinal fluid (CSF) and accumulate in the retina. Aβ is known to cause tau hyperphosphorylation, leading to its buildup in various retinal layers.

The role of intestinal microbiota and its metabolite short-chain fatty acids in hypertriglyceridemia-associated acute pancreatitis

Hypertriglyceridemia-associated acute pancreatitis (HLAP) is a severe gastrointestinal condition characterized by an increased risk of multiple organ dysfunction and elevated mortality. Intestinal microbiota, often described as the second human genome, plays a key role in maintaining gastrointestinal and systemic homeostasis. Among its various metabolites, short-chain fatty acids (SCFAs) are particularly abundant and functionally significant. Current evidence indicates a strong relationship between SCFAs and the pathogenesis and progression of HLAP. SCFAs contribute to the restoration of intestinal homeostasis by modulating the composition of gut microbiota, enhancing the integrity of the intestinal epithelial barrier, and regulating mucosal immune responses. Furthermore, SCFAs attenuate systemic inflammatory responses, promote pancreatic tissue repair, and reduce the risk of multiple organ dysfunction. These protective effects indicate that SCFAs represent a promising therapeutic target for gut-centered interventions in HLAP. This review summarizes the changes in intestinal microbiota and SCFA levels following HLAP onset, elucidates the underlying mechanisms by which SCFAs exert protective effects, and evaluates their potential therapeutic applications, thereby providing a theoretical basis for the development of gut-targeted strategies in the management of HLAP.

Acute pancreatitis (AP) is characterized by acute inflammation and cellular injury within the pancreas and is recognized as a common cause of acute abdominal disorders. With improvements in living standards and shifts in dietary habits, the incidence of hypertriglyceridemia-associated acute pancreatitis (HLAP) has significantly increased, surpassing alcoholic pancreatitis to become the second leading cause of AP (Chinese Pancreatic Surgery Association, and Chinese Society of Surgery, Chinese Medical Association, 2021). Additionally, HLAP is increasingly observed in younger adults and is associated with severe clinical presentations, including a higher incidence of complications such as acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and multiple organ dysfunction syndrome (MODS) (Li et al., 2018).

New photonic chips passively convert laser light into multiple colors on demand

Over the past several decades, researchers have been making rapid progress in harnessing light to enable all sorts of scientific and industrial applications. From creating stupendously accurate clocks to processing the petabytes of information zipping through data centers, the demand for turnkey technologies that can reliably generate and manipulate light has become a global market worth hundreds of billions of dollars.

One challenge that has stymied scientists is the creation of a compact source of light that fits onto a chip, which makes it much easier to integrate with existing hardware. In particular, researchers have long sought to design chips that can convert one color of laser light into a rainbow of additional colors—a necessary ingredient for building certain kinds of quantum computers and making precision measurements of or time.

Now, researchers at JQI have designed and tested new chips that reliably convert one color of light into a trio of hues. Remarkably, the chips all work without any active inputs or painstaking optimization—a major improvement over previous methods. The team described their results in the journal Science on Nov. 6, 2025.

/* */